210 related articles for article (PubMed ID: 35247926)
1. Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma.
Levi ST; Copeland AR; Nah S; Crystal JS; Ivey GD; Lalani A; Jafferji M; White BS; Parikh NB; Leko V; Krishna S; Lowery F; Prickett TD; Gartner JJ; Jia L; Li YF; Sachs A; Sindiri S; Robinson W; Gasmi B; Yang JC; Goff SL; Rosenberg SA; Robbins PF
Clin Cancer Res; 2022 Jul; 28(14):3042-3052. PubMed ID: 35247926
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?
Blass E; Ott PA
Clin Cancer Res; 2022 Jul; 28(14):2980-2982. PubMed ID: 35576171
[TBL] [Abstract][Full Text] [Related]
3. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
[TBL] [Abstract][Full Text] [Related]
4. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
5. Neoantigen-specific CD4
Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
[TBL] [Abstract][Full Text] [Related]
6. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS; Mullinax JE; Cox CA; Hall AM; Beatty MS; Blauvelt J; Innamarato P; Nagle L; Branthoover H; Wiener D; Schachner B; Martinez AJ; Richards AD; Rich CJ; Colón Colón M; Schell MJ; Teer JK; Khushalani NI; Weber JS; Mulé JJ; Sondak VK; Pilon-Thomas S; Sarnaik AA
Clin Cancer Res; 2022 Dec; 28(24):5317-5329. PubMed ID: 36215121
[TBL] [Abstract][Full Text] [Related]
7. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
10. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
11. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.
Kast F; Klein C; Umaña P; Gros A; Gasser S
Oncoimmunology; 2021 Jan; 10(1):1869389. PubMed ID: 33520408
[TBL] [Abstract][Full Text] [Related]
12. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
13. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073
[TBL] [Abstract][Full Text] [Related]
14. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
15. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
18. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S; Wolf Y; Feferman T; Barnea E; Greenstein E; Reshef D; Tirosh I; Reuben A; Patkar S; Levy R; Quinkhardt J; Omokoko T; Qutob N; Golani O; Zhang J; Mao X; Song X; Bernatchez C; Haymaker C; Forget MA; Creasy C; Greenberg P; Carter BW; Cooper ZA; Rosenberg SA; Lotem M; Sahin U; Shakhar G; Ruppin E; Wargo JA; Friedman N; Admon A; Samuels Y
Cancer Discov; 2018 Nov; 8(11):1366-1375. PubMed ID: 30209080
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
20. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
